The effects of old, new and emerging medicines on metabolic aberrations in PCOS

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age that is associated with significant adverse short-and long-term health consequences. Multiple metabolic aberrations, such as insulin resistance (IR) and hyperinsulinaemia, high incidence of impaired glucose tolerance, visceral obesity, inflammation and endothelial dysfunction, hypertension and dyslipidemia are associated with the syndrome. Assessing the metabolic aberrations and their long term health impact in women with PCOS is challenging and becomes more important as therapeutic interventions currently available for the management of PCOS are not fully able to deal with all these consequences. Current therapeutic management of PCOS has incorporated new treatments resulting from the better understanding of the pathophysiology of the syndrome. The aim of this review is to summarize the effect of old, new and emerging therapies used in the management of PCOS, on the metabolic aberrations of PCOS

Bak Foong pills combined with metformin in the treatment of a polycystic ovarian syndrome rat model

“…The insulin sensitizer, metformin, can cause reductions in body weight, restore ovulation, increase the rate of pregnancy and reduce the number of pregnancy complications (15)(16)(17)(18). Our previous study successfully established a PCOS rat model that could simulate the clinical and biochemical characteristics of PCOS.…”

Pilot Study of Alternative Therapy with Minerals in Patients of Polycystic Ovary Syndrome

“…Individual minerals have shown advantageous role in PCOS patient as a natural therapy but specific combination of minerals with well-designed specific technique was not studied till date [2,7]. Present study was carried out on hypothesis of utilizing the natural mineral base containing practically every known element …”

“…PCOS is defined by hyperandrogenism (clinical or biochemical), chronic anovulation, and/or polycystic ovaries with the exclusion of the adrenal, ovary and pituitary disorders. It is also character ized by multiple metabolic aberrations such as insulin resistance (IR) and hyperinsuli naemia, high incidence of impaired glucose tolerance visceral obesity, inflammation and endothelial dysfunction, hypertension and dys lipidemia resulting in an increased risk for dia betes and clinical or subclinical cardiovascular disease [2]. Compromised quality of life, anxiety and depres sion are also observed in PCOS.…”

“…Compromised quality of life, anxiety and depres sion are also observed in PCOS. PCOS is now considered as a female subtype of the metabolic syndrome and its potential health consequences are a lifelong issue [2].…”

National consensus on the management of patients with hyperandrogenism (2016)

“…Крім того, викори-стання комбінованих гормональних контрацептивів до-стовірно знижує ризик раку ендометрія [69]. В пацієнток із СПКЯ препарати із залишковою андрогенною активністю можуть посилювати ІР [39,70,71].…”